Tango Therapeutics to Participate in the Jefferies London Healthcare Conference
Tango Therapeutics (NASDAQ: TNGX) announced participation in the Jefferies London Healthcare Conference on November 18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) announced participation in the Jefferies London Healthcare Conference on November 18, 2021. The management team will present, with the session available on-demand starting at 8 AM GMT. A replay will be accessible for 30 days on the company's website. Tango focuses on precision cancer medicine, leveraging synthetic lethality to target cancer cells and enhance treatment efficacy. For more details, visit tangotx.com.
Details
News Market Reaction – TNGX
The recorded move for TNGX in the trading session of this news was +1.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the the Jefferies London Healthcare Conference. The presentation will be available on-demand starting at 8 AM GMT on Thursday, November 18, 2021.
A webcast of the event will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Investor Contact:
Sam Martin
Argot Partners
tango@argotpartners.com
Media Contact:
Joshua R. Mansbach
Argot Partners
tango@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.